177 related articles for article (PubMed ID: 32274723)
1. PI-88 and Related Heparan Sulfate Mimetics.
Chhabra M; Ferro V
Adv Exp Med Biol; 2020; 1221():473-491. PubMed ID: 32274723
[TBL] [Abstract][Full Text] [Related]
2. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.
Dredge K; Hammond E; Davis K; Li CP; Liu L; Johnstone K; Handley P; Wimmer N; Gonda TJ; Gautam A; Ferro V; Bytheway I
Invest New Drugs; 2010 Jun; 28(3):276-83. PubMed ID: 19357810
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
4. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.
Parish CR; Freeman C; Brown KJ; Francis DJ; Cowden WB
Cancer Res; 1999 Jul; 59(14):3433-41. PubMed ID: 10416607
[TBL] [Abstract][Full Text] [Related]
5. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Hammond E; Dredge K
Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
[TBL] [Abstract][Full Text] [Related]
6. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.
Ferro V; Dredge K; Liu L; Hammond E; Bytheway I; Li C; Johnstone K; Karoli T; Davis K; Copeman E; Gautam A
Semin Thromb Hemost; 2007 Jul; 33(5):557-68. PubMed ID: 17629854
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.
Johnstone KD; Karoli T; Liu L; Dredge K; Copeman E; Li CP; Davis K; Hammond E; Bytheway I; Kostewicz E; Chiu FC; Shackleford DM; Charman SA; Charman WN; Harenberg J; Gonda TJ; Ferro V
J Med Chem; 2010 Feb; 53(4):1686-99. PubMed ID: 20128596
[TBL] [Abstract][Full Text] [Related]
8. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections.
Chhabra M; Wilson JC; Wu L; Davies GJ; Gandhi NS; Ferro V
Chemistry; 2022 Feb; 28(11):e202104222. PubMed ID: 34981584
[TBL] [Abstract][Full Text] [Related]
9. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.
Khachigian LM; Parish CR
Cardiovasc Drug Rev; 2004; 22(1):1-6. PubMed ID: 14978514
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, radiolabeling with fluorine-18 and preliminary in vivo evaluation of a heparan sulphate mimetic as potent angiogenesis and heparanase inhibitor for cancer applications.
Kuhnast B; El Hadri A; Boisgard R; Hinnen F; Richard S; Caravano A; Nancy-Portebois V; Petitou M; Tavitian B; Dollé F
Org Biomol Chem; 2016 Feb; 14(6):1915-20. PubMed ID: 26757783
[TBL] [Abstract][Full Text] [Related]
11. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
12. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
13. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Ferro V; Liu L; Johnstone KD; Wimmer N; Karoli T; Handley P; Rowley J; Dredge K; Li CP; Hammond E; Davis K; Sarimaa L; Harenberg J; Bytheway I
J Med Chem; 2012 Apr; 55(8):3804-13. PubMed ID: 22458531
[TBL] [Abstract][Full Text] [Related]
14. Heparanase: Historical Aspects and Future Perspectives.
Khanna M; Parish CR
Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
16. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity.
Koliesnik IO; Kuipers HF; Medina CO; Zihsler S; Liu D; Van Belleghem JD; Bollyky PL
Front Immunol; 2020; 11():132. PubMed ID: 32117279
[TBL] [Abstract][Full Text] [Related]
17. The heparan sulfate mimetic Muparfostat aggravates steatohepatitis in obese mice due to its binding affinity to lipoprotein lipase.
Zhang J; Li K; Sun HR; Sun SK; Zhu YT; Ge YT; Wu YX; Zhou QY; Li GT; Chang XA; Sun P; Ding Y; Han X
Br J Pharmacol; 2023 Jul; 180(14):1803-1818. PubMed ID: 36735592
[TBL] [Abstract][Full Text] [Related]
18. Oligosaccharides from fucosylated glycosaminoglycan prevent breast cancer metastasis in mice by inhibiting heparanase activity and angiogenesis.
Zhou L; Yin R; Gao N; Sun H; Chen D; Cai Y; Ren L; Yang L; Zuo Z; Zhang H; Zhao J
Pharmacol Res; 2021 Apr; 166():105527. PubMed ID: 33667689
[TBL] [Abstract][Full Text] [Related]
19. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
20. Development of Improved Synthetic Routes to Pixatimod (PG545), a Sulfated Oligosaccharide-Steroid Conjugate.
Chhabra M; Wimmer N; He QQ; Ferro V
Bioconjug Chem; 2021 Nov; 32(11):2420-2431. PubMed ID: 34652896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
